Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-1999

Clinical Infectious Diseases

Volumn 32, Issue 10 SUPPL. 2, 2001, Pages

  Low, D E ^a   Keller, N ^a   Barth, A ^a   Jones, R N ^a  

^a The JONES Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CENTRAL AMERICA; CONFERENCE PAPER; ENTEROCOCCUS; EUROPE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; NONHUMAN; NORTH AMERICA; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SOUTH AMERICA;

EID: 0035873658     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320185     Document Type: Conference Paper

References (90)

1. Major trends in the microbial etiology of nosocomial infection
2. Enterococcus species, Streptococcus bovis, and Leuconostoc species
3. Management of infections due to resistant enterococci: A review of therapeutic options
4. Diversity among multidrug-resistant enterococci
5. An overview of nosocomial infections, including the role of the microbiology laboratory
6. Nosocomial enterococcal blood stream infections in the SCOPE program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy
7. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993: National Nosocomial Infection Surveillance
8. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
9. Enterococci and vancomycin resistance
10. Mechanisms of glycopeptide resistance in enterococci
11. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum
12. Current perspectives on glycopeptide resistance
13. VanD-type glycopeptide-resistant Enterococcus faecium BM4339
14. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM 4405
15. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycinresistant enterococci
16. Vancomycin-resistant enterococci. Mechanism and clinical relevance
17. Vancomycin-resistant enterococci
18. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: A 22-year review at one institution
19. Beta-lactamase-producing enterococci
20. Ampicillin-resistant enterococcal species in an acute-care hospital
21. Enterococci highly resistant to penicillin and ampicillin: An emerging clinical problem?
22. Rapid increase in the prevalence of high-level aminoglycoside resistance among enterococci isolated from blood cultures during 1989-1991
23. Vancomycin-resistant enterococci
24. Vancomycin resistant enterococci in hospitals in the United Kingdom
25. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance
26. Epidemic vancomycin-resistant Enterococcus faecium in the UK
27. Epidemiology of glycopeptide-resistant enterococci colonizing high-risk patients in hospitals in Johannesburg, Republic of South Africa
28. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States
29. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance studies in the United States
30. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center
31. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
32. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
33. Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
34. Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, 1997
35. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant grampositive bacteria: The role of streptogramins and other newer compounds
36. Evaluation of Vitek and AP1 20S for species identification of enterococci
37. Vancomycin-resistant Enterococcus raffinosus: Molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program
38. Identification of Enterococcus species isolated from human infections by a conventional test scheme
39. Practical approach to the identification of clinically relevant Enterococcus species
40. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR
41. Automation of polymerase chain reaction tests to achieve acceptable contamination rates
42. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HIC-PAC)
43. Guideline for isolation precautions in hospitals
44. Antimicrobial activity of SCH 27899, oligosaccharide member of the everninomycin class with a wide gram-positive spectrum
45. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
46. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium
47. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
48. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcusfaecium bacteremia
49. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium
50. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
51. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
52. Resistance of enterococci to glycopeptides
53. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
54. vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Corynebacterium) haemolyticum
55. Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis
56. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
57. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
58. Emergence of vancomycin resistance in coagulase-negative staphylococci
59. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
60. Spread of vancomycin-resistant enterococci: Differences between the United States and Europe
61. Vancomycin-resistant enterococci outside the health-care setting: Prevalence, sources, and public health implications
62. Historical yearly usage of vancomycin
63. The epidemiology of intravenous vancomycin usage in a university hospital: A 10-year study
64. Epidemiology, appropriateness, and cost of vancomycin use
65. Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci
66. vanA-mediated vancomycin-resistant Enterococcus spp in sewage
67. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man
68. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium
69. Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community
70. Colonization by vancomycinresistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals
71. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands
72. Prevalence of vancomycinresistant enterococci in fecal samples from hospitalized patients and nonhospitalized controls in cattle-rearing areas of France
73. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States
74. Vancomycin-resistant enterococci in turkeys and farmers
75. Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers
76. Resistance to glycopeptides in enterococci
77. Antimicrobial susceptibility patterns of enterococci causing infections in Europe
78. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci
79. Resistance to vancomycin and teicoplanin: An emerging clinical problem
80. Emerging multiply resistant enterococci among clinical isolates. II. Validation of the Etest to recognize glycopeptide-resistant strains
81. Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci
82. Study to determine the ability of clinical laboratories to detect antimicrobial-resistant Enterococcus spp. in Buenos Aires, Argentina
83. Bacterial resistance: A worldwide problem
84. Surveillance of the current resistance of nosocomial pathogens to antibacterials
85. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients
86. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance